KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) EPS (Basic) (2017 - 2025)

Historic EPS (Basic) for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $754.8 million.

  • Takeda Pharmaceutical's EPS (Basic) fell 1084.56% to $754.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $754.8 million, marking a year-over-year decrease of 1084.56%. This contributed to the annual value of $1.6 billion for FY2025, which is 24724559745740.64% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's EPS (Basic) stood at $754.8 million, which was down 1084.56% from $9.8 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year EPS (Basic) high stood at $9.8 billion for Q3 2023, and its period low was -$77.2 million during Q1 2022.
  • For the 5-year period, Takeda Pharmaceutical's EPS (Basic) averaged around $2.3 billion, with its median value being $1.3 billion (2022).
  • As far as peak fluctuations go, Takeda Pharmaceutical's EPS (Basic) tumbled by 10942.76% in 2022, and later surged by 1245541.31% in 2025.
  • Over the past 5 years, Takeda Pharmaceutical's EPS (Basic) (Quarter) stood at $374.9 million in 2021, then skyrocketed by 72.39% to $646.3 million in 2022, then soared by 161.77% to $1.7 billion in 2023, then crashed by 49.96% to $846.6 million in 2024, then fell by 10.85% to $754.8 million in 2025.
  • Its last three reported values are $754.8 million in Q4 2025, $9.8 billion for Q3 2025, and $2.7 billion during Q2 2025.